Gilead Sciences is a biopharmaceutical company focused on the research, development, and commercialization of innovative medicines. Its core products include antiviral therapies for HIV, hepatitis B, hepatitis C, and influenza, as well as treatments for cancer and inflammatory diseases. Major business segments consist of antiviral and oncology products, with primary revenue sources stemming from sales of these therapies. The company is recognized for its contributions to public health through its advanced drug formulations and research initiatives.
Gilead Sciences presents a profile more aligned with dividend investors due to its consistent dividend yield. The stock may appeal to those seeking income rather than aggressive growth, given its established market presence and product portfolio. However, recent revenue declines suggest caution for value investors. The stock may suit a balanced approach, considering its potential for moderate returns alongside dividend income.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-06-09 02:40 | Hold | Sell | Weak fundamentals and negative momentum raise concerns. |
| 2026-06-01 02:39 | Buy | Hold | Weak fundamentals and mixed momentum signal caution. |
| 2026-05-24 02:40 | Hold | Buy | Mixed performance; cautious due to revenue decline. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-06-01 11:47 | RBC Capital | Update | — → 122 | 134.43 |
| 2026-05-20 12:15 | Maxim Group | Rating Upgraded | — → 165 | 130.5492 |
| 2026-05-10 14:41 | Morgan Stanley | Target Lowered | 175 → 168 | 131.33 |
